Comparison of the Modified Low-Dose Cytarabine with 5-Day Decitabine Therapy for Elderly AML Patients Unfit for Intensive Chemotherapy
Classical low-dose cytarabine (LDAC; ≤ 20 mg SQ BID for 10 days) remains a standard option for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, although long-term results were unsatisfactory. Recently, hypomethylating agents, such as decitabine and azacitidine, have been proved to have better outcomes t han the classical LDAC.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Byung Sik Cho, Seung-Hwan Shin, Jae-Ho Yoon, Yun-Ho Ko, Ki-Sung Eom, Hee-Je Kimi, Woo-Sung Min Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma